Senior Vice President
Tango Therapeutics
Senior Vice President
Tango Therapeutics
Develops synthetic-lethality cancer therapies
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
The Senior Vice President (SVP) of Market Access is a critical enterprise leader responsible for architecting and executing the overarching market access, patient services, pricing, and distribution vision for Tango Therapeutics. As the company transitions from a research-stage biotech into a fully integrated commercial organization, this executive will define the access roadmap for our pipeline of precision synthetic lethality oral medicines.
Reporting directly to the Chief Commercialization Officer and serving as a key pillar of the Commercial Leadership Team, the SVP will build a world-class market access infrastructure from the ground up. This leader will ensure that the clinical promise of our assets is met with frictionless patient access, optimized commercial value, and sustainable market positioning on a global scale.
Your Role:
Enterprise leadership & Organizational Design
Strategic Priorities:
Global Value & Health Economics
Pricing, Payer Strategy & Policy
Channel Architecture & Patient Experience
What You Bring:
Education & Experience
Core Competencies
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Salary range 337600 - 506400 USD
Develops synthetic-lethality cancer therapies
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Explore more opportunities at Tango Therapeutics